The young scientist Philippe Vollmer Barbosa with cell cultures for the production of the virus vectors that are to bring the drug into the lung cells as a gene taxi ; Copyright: Karin Kaiser / MHH
The young scientist Philippe Vollmer Barbosa with cell cultures for the production of the virus vectors that are to bring the drug into the lung cells as a gene taxi ; Copyright: Karin Kaiser / MHH Research project iGUARD receives follow-up funding for the development of RNA-based drugs Despite successful vaccine development, there are still no effective drugs for most viral diseases. This should change as soon as possible. With the project "iGUARD (integrated Guided Ultrafast Antiviral RNAi Drug development)", a research team led by Axel Schambach, head of the Institute for Experimental Haematology at the Hannover Medical School (MHH), is developing RNA-based drugs to combat viral diseases in cooperation with the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, using a natural mechanism of our body. The drugs should be able to adapt particularly quickly to different viruses and thus provide protection against emerging infectious diseases. Systematically blocking virus replication. The iGUARD research team is focusing on the parainfluenza virus, which primarily attacks the lower respiratory tract in children and people with weakened immune systems. It triggers flu-like symptoms, but its course can also be very severe.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
